Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme by Lisa BE Shields et al.
Shields et al. Radiation Oncology 2013, 8:101
http://www.ro-journal.com/content/8/1/101RESEARCH Open AccessConcurrent bevacizumab and temozolomide alter
the patterns of failure in radiation treatment of
glioblastoma multiforme
Lisa BE Shields1,2, Robert Kadner3, Todd W Vitaz1,2 and Aaron C Spalding2,4,5*Abstract
Background: We investigated the pattern of failure in glioblastoma multiforma (GBM) patients treated with
concurrent radiation, bevacizumab (BEV), and temozolomide (TMZ). Previous studies demonstrated a predominantly
in-field pattern of failure for GBM patients not treated with concurrent BEV.
Methods: We reviewed the treatment of 23 patients with GBM who received 30 fractions of simultaneous
integrated boost IMRT. PTV60 received 2 Gy daily to the tumor bed or residual tumor while PTV54 received 1.8 Gy
daily to the surrounding edema. Concurrent TMZ (75 mg/m^2) daily and BEV (10 mg/kg every 2 weeks) were given
during radiation therapy. One month after RT completion, adjuvant TMZ (150 mg/m^2 × 5 days) and BEV were
delivered monthly until progression or 12 months total.
Results: With a median follow-up of 12 months, the median disease-free and overall survival were not reached.
Four patients discontinued therapy due to toxicity for the following reasons: bone marrow suppression (2),
craniotomy wound infection (1), and pulmonary embolus (1). Five patients had grade 2 or 3 hypertension managed
by oral medications. Of the 12 patients with tumor recurrence, 7 suffered distant failure with either subependymal
(5/12; 41%) or deep white matter (2/12; 17%) spread detected on T2 FLAIR sequences. Five of 12 patients (41%)
with a recurrence demonstrated evidence of GAD enhancement. The patterns of failure did not correlate with
extent of resection or number of adjuvant cycles.
Conclusions: Treatment of GBM patients with concurrent radiation, BEV, and TMZ was well tolerated in the current
study. The majority of patients experienced an out-of-field pattern of failure with radiation, BEV, and TMZ which has
not been previously reported. Further investigation is warranted to determine whether BEV alters the underlying
tumor biology to improve survival. These data may indicate that the currently used clinical target volume thought
to represent microscopic disease for radiation may not be appropriate in combination with TMZ and BEV.
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Approximately 18,000 individuals are diagnosed annually
with malignant primary brain tumors in the United
States; more than half of these patients have GBM [1].
The current standard of care for newly diagnosed GBM
is surgical resection followed by adjuvant radiotherapy
with TMZ [2].* Correspondence: acspalding1@gmail.com
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reproduction in any medium, provided the orRadiation therapy following the initial surgical debulking
procedure of the GBM represents one of the most effect-
ive postoperative treatment modalities. The volume of
tumor treated has ranged from lower dose whole brain
irradiation to higher dose focal tumor irradiation over the
past thirty years in order to reduce the likelihood of
normal tissue damage. Despite whole brain irradiation,
most patients progress near or within the original tumor
location. The primary goal in the treatment planning stage
is to emphasize the dose delivery to the tumor volume
while sparing the normal tissue [3,4].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ity of patterns of failure following radiation were within
the high dose in-field suggesting local tumor recurrence
in close proximity to the primary tumor site [5-8]. Both
BEV and TMZ have shown efficacy in conjunction with
radiation in the treatment of recurrent GBMs [9-12], and
BEV has been shown in vitro and in animal models to
alter GBM cell migration [13]. Therefore, we investigated
whether this intensification of therapy with biological
agents altered the pattern of failure in patients with GBM.
Methods
Under an IRB-approved protocol and in compliance with
the Helsinki Declaration, we retrospectively reviewed the
treatment of 23 patients with newly diagnosed GBM who
received post-operative 30 fractions of simultaneous inte-
grated boost IMRT (Intensity-Modulated Radiation
Therapy). The patients did not have any evidence of
multifocal disease. The extent of resection (gross total,
subtotal, or biopsy only) was determined on 24 hour post-
operative MRI. Postoperative MRI scans were fused with
the radiation planning CT scan. Targets were delineated
according to RTOG guidelines with the GTV1 containing
the postoperative T2 FLAIR abnormality, any postopera-
tive enhancement, and the surgical cavity expanded
2.5 cm to generate the PTV60. GTV2 included the enhan-
cing abnormality on the postoperative scan and surgical
cavity and was expanded 1.5 cm to generate the PTV54.
Concurrent TMZ (75 mg/m^2) daily and BEV (10 mg/kg
every 2 weeks) were given during radiation therapy for
6 weeks. One month after completion of RT, adjuvant
TMZ (150 mg/m^2 × 5 days) and BEV were delivered
monthly until progression or 12 months total. An MRI
scan with GAD was performed before initiation of adju-
vant therapy and then every 3 months. Figure 1 depicts
the treatment regimen.
Progression was defined as new T1 Gadolinium en-
hancement or T2 FLAIR progression, based on the RANOFigure 1 Treatment regimen of radiation therapy with BEV and TMZcriteria [14]. The MRIs were independently reviewed by a
neuroradiologist who was blinded to the previous radi-
ation IDV (Isodose Volume). Recurrences were scored as
in field (95% of recurrence volume in the 57 Gy, [95%] iso-
dose volume), marginal (95% of the recurrence volume
within the 48 Gy [80%] isodose volume), or distant
(subepedymal versus deep white matter), consistent with
prior reported studies [5,7,8]. In patients with recurrence
based on progression of T2/FLAIR imaging, the diagnosis
was made based on a combination of factors including
mass effect, the development of new lesions, or the pres-
ence of progressive edema remote from the resection
cavity. The time point of recurrence in these cases was
based on the first sign of progressive disease, whether seen
on FLAIR or T1 with Gadolinium. A biopsy was not
performed due to the risk of complications as well as
potential delay in additional anti-GBM therapy.
Results
A total of 23 patients were enrolled in the study with an
age range between 28 and 76 years (median age 55 years).
Of the total 23 patients, the extent of resection of tumor
was as follows: Gross total: 14 (61%), subtotal: 5 (22%),
and biopsy only: 4 (17%). Table 1 summarizes the patient
characteristics. Of the 10 patients who underwent
methylation status testing, methylation of the MGMT
promoter was observed in 5 of 10 patients (50%).
With a median follow-up of 12 months, the median
disease-free and overall survival was not reached. A total
of 6 patients completed the full 12 cycles of adjuvant
systemic therapy. The median number of cycles com-
pleted was four. Four patients discontinued therapy due
to toxicity for the following reasons: bone marrow
suppression (2), craniotomy wound infection (1), and
pulmonary embolus (1). Three patients completed 3 or
4 cycles at the time of analysis without tumor progres-
sion or toxicity. Five patients had grade 2 or 3 hyperten-
sion that was managed by oral medications.for GBM.
Table 1 Characteristics of patients with newly diagnosed
GBM treated with radiation, BEV, and TMZ








Gross Total Resection 14 (61%)
Subtotal Resection 5 (22%)
Biopsy Only 4 (17%)
Number of BEV cycles
Range 1–13
Median 4




Alive, without Progression 11 (48%)
Alive, with Progression of Disease 3 (13%)
Deceased from Disease 9 (39%)
Shields et al. Radiation Oncology 2013, 8:101 Page 3 of 7
http://www.ro-journal.com/content/8/1/101Twelve of the 23 patients experienced a tumor recur-
rence (Figure 2a, b). Of the 12 patients with a recur-
rence, three patients (3/12; 25%) had in-field failure, and
two (2/12; 17%) had marginal failure. Seven patients
demonstrated distant failure with either subependymal
(5/12; 41%) or deep white matter (2/12; 17%) spread
detected on T2 FLAIR sequences. The pattern of recur-
rence on T2 was a combination of increased signal in
the subependymal white matter, the corpus callosum,
and in the fiber tracts of the corona radiata and centrum
semiovale. The only leptomeningeal disease was that
seen with GAD on T1. Table 2 highlights the patterns of
failure with respect to number of cycles completed, the
extent of resection, and the failure IDV. Five of twelve
patients (41%) with a recurrence demonstrated evidence
of GAD enhancement, specifically, in-field (3 of 5
patients) and marginal (2 of 5 patients). The pattern of
failure observed in this study was statistically different
with a P < 0.05 by ANOVA compared to published stud-
ies (Table 3).
Of the 12 patients who experienced a tumor recur-
rence, 10 had clinical symptoms which preceded the
tumor progression detected on MRI. The symptoms
included a change in mental status, new weakness of a
limb, speech changes, and headaches. The tumor recur-
rences occurred between 132–560 days postoperatively
(median: 256 days). The earliest recurrence occurred within
84 days postoperatively outside of the high dose IDV, whichis not consistent with pseudoprogression. The tumor recur-
rence of two patients was noted on MRI prior to the initi-
ation of symptoms 256 and 285 days postoperatively,
respectively. However, both of these patients began experi-
encing symptoms within 3 weeks of imaging progression,
and one died within one month of new symptoms.
Discussion
Angiogenesis is necessary for the development of macro-
scopic neoplasia [15]. GBM exhibit a host of pathological
features, including loss of blood-brain barrier integrity,
endothelial proliferation, marked hypoxia, and tumor
necrosis [11]. Attention has focused on developing
antiangiogenic therapies that target either the vascular
endothelial growth factor (VEGF) or vascular endothelial
growth factor receptor (VEGFR) [9]. Several mechanisms
of anti-VEGF agents in brain tumors have been proposed
such as vascular normalization leading to improved tissue
oxygenation and drug delivery, sensitization of endothelial
cells to cytotoxic agents specifically radiation, and direct
anti-glioma stem cell effect [9,11]. The most commonly ob-
served side effects with BEV include hypertension, fatigue,
and thrombosis with rare intratumor hemorrhage [9].
Both TMZ and BEV are recognized to provide clinical
benefits for GBM patients [9-12]. TMZ is an alkylating
agent which is rapidly absorbed and highly bioavailable
after oral administration which simplifies patient dosing
[10]. TMZ also crosses the blood-brain barrier to attain
an effective concentration in the CNS [10]. The addition
of TMZ to radiation has been shown in a randomized
trial to improve survival in GBM patients [12]. BEV is
an anti-VEGF monoclonal antibody which neutralizes
VEGF, may decrease cerebral edema, and has been
shown to improve survival in patients with progressive
GBM compared with historical control [11,16]. BEV
combined with cytotoxic chemotherapy (CPT-11 or
carboplatin) have been shown to interrupt VEGF signal-
ing causing sensitization or reversal of cytotoxic drug
resistance, improvement in cytotoxic drug vascular ac-
cess through vascular normalization, and a reduction in
tumor interstitial pressure [9].
Based on these observations, investigators have studied
the addition of BEV to the standard radiation and TMZ
regimen. Lai and colleagues treated patients with external
beam radiation of 60.0 Gy after the surgery concurrently
with TMZ and BEV [17,18]. Upon completion of the radi-
ation, patients continued to receive TMZ and BEV. They
observed toxicities in their studies including radiation-
induced optic neuropathy, retinal detachment, fatigue,
myelotoxicty, wound breakdown, and deep venous throm-
bosis/pulmonary embolism [17,18]. Vredenburgh and col-
leagues investigated adding BEV to a combination of
59.4 Gy radiation and TMZ followed by a cocktail of BEV,
TMZ, and irinotecan after the completion of the radiation
Figure 2 (a, b) Patterns of failure following radiation therapy with BEV and TMZ for GBM. Subependymal; Deep white matter; In-field
failure (95% of recurrence volume in the 57 Gy, [95%] isodose volume); and Marginal failure (95% of the recurrence volume within the 48 Gy
[80%] isodose volume).
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thrombosis/pulmonary embolism, gastrointestinal toxicity
(bowel perforation, rectal abscess, and sepsis), fatigue,
Pneumocysitis carinii pneumonia, and optic neuritis.
While these side effects were noted in their patient popu-
lation, Vredenburgh et al. reported the overall safety of
adding BEV to radiation therapy and TMZ [19]. In
Narayana et al.’s study, patients with a newly diagnosed
GBM were treated with a combination of 59.4 Gy radi-
ation, TMZ, and BEV [21]. Although a total of 20% of pa-
tients experienced Grade III/IV toxicities including
thrombocytopenia, deep vein thrombosis, and pulmonary
embolism, the authors reported that the addition of BEV
to conventional therapy in the treatment of newly diag-
nosed GBM improved PFS and OS compared with histor-
ical controls [21].The median follow-up of the present study was
12 months. While the median overall survival was not
reached, the 6 month progression-free survival was
promising (87%). In the current study, combined therapy
of radiation in conjunction with BEV and TMZ to treat
GBM proved successful with minimal toxicity. Four
patients discontinued therapy due to toxicity for the fol-
lowing: bone marrow suspension (2), craniotomy wound
infection (1), and pulmonary embolus (1). Five patients
had grade 2 or 3 hypertension that was managed by oral
medications.
The determination of tumor progression in this study
was based on new T1 Gadolinium enhancement or T2
FLAIR progression, based on the RANO criteria [14]. A
biopsy was not performed due to the risk of complica-
tions as well as potential delay in additional anti-GBM
Table 2 The patterns of failure following radiation for GBM with respect to cycles completed, extent of resection, and
failure isodose volume
Patient number Pattern of failure Cycles completed Extent of resection Failure IDV (Gy) Failure IDV (%)
1 In-Field 7 GTR 58 96
2 In-Field 7 GTR 57 95
3 In-Field 12 GTR 58 97
4 Marginal 4 GTR 49 81
5 Marginal 5 STR 51 85
6 Subependymal 3 STR 24 40
7 Subependyma1 3 STR 12 20
8 Subependymal 3 Biopsy 21 35
9 Subependymal 3 STR 25 42
10 Subependymal 6 GTR 26 43
11 Deep White Matter 4 GTR 12 21
12 Deep White Matter 10 Biopsy 5 8
GTR: Gross Total Resection.
STR: Subtotal Resection.
IDV: Isodose Volume.
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outweighed the benefit of conducting a biopsy as prior
BEV increases complications. Ten of the 12 patients
who experienced a tumor recurrence had clinical symp-
toms prior to tumor progression detected on MRI.
These new symptoms included a change in mental
status, new weakness of a limb, speech changes, and
headaches. Two of the 12 patients with a tumor recur-
rence denied any symptoms prior to the tumor detection
on MRI. However, both of these patients began experi-
encing symptoms within 3 weeks of imaging progres-
sion, and one died within one month of new symptoms.
As the radiation treatment of GBM has evolved, investi-
gators have analyzed the patterns of failure to determine
whether the target volume margin was sufficient or
whether it requires redefinition prior to subsequent trials
[22]. In the 1970s the RTOG determined that the dose of
60 Gy was appropriate to administer to GBM patients
[23]. As technology improved, investigators have steadily
increased the radiation dose as repeated patterns of failure
analysis have shown primarily in-field recurrences with
the hypothesis that increased radiation will improve tumorTable 3 The patterns of failure following radiation for GBM w
percentage of in-field failure
Study Year Number of patients Radiation techniq
Current study 2013 23 IMRT
Lee [22] 1999 36 3DCRT
Hess [24] 1994 66 3DCRT
Garden [7] 1991 39 3DCRT
Wallner [8] 1989 25 Whole Brain + Boos
Fitzek [6] 1999 23 Sequential Boost 3D
Chan [5] 2002 34 Sequential Boost 3Dcontrol. Table 3 depicts the patterns of failure following
radiation for high-grade gliomas in a host of studies in the
literature with special attention to the radiation regimen
and dose [5-8,22,24]. The majority (71%–91%) of failures
were in-field. Three studies are of particular note within
Table 3 due to dose escalation beyond 60 Gy. Fitzek et al.
used sequential boost 3DCRT with photons and protons
and a dose of 90 CGE to treat GBM patients [6]. The in-
field failure was 78% with a median survival time of
20 months. Lee et al. utilized 3DCRT with either 70 or
80 Gy and demonstrated an 89% in-field failure [22]. They
proposed dose escalation to 90 Gy and beyond while
maintaining the same target volume definition criteria
[22]. As a follow-up, Chan et al. used sequential boost
3DCRT with a dose escalation to 90 Gy and reported an
in-field failure of 91% [5]. They suggested that intensifica-
tion of local radiotherapy with dose escalation was feasible
and warranted further evaluation [5]. Taken together,
these studies suggest that radiation dose escalation alone
is unlikely to produce clinical benefit for GBM patients.
Two recent trials have randomized patients to the
standard radiation and TMZ regiment with or withoutith respect to radiation techniques, radiation dose, and
ues Dose % In-field failure
60 Gy 25% (p < .05)
70 or 80 Gy 89%
60 Gy 86%
65.4 Gy 71%
t 70 Gy 75%
CRT with photons and protons 90 CGE 78%
CRT 90 Gy 91%
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clinical benefit. The Avaglio phase III trial with BEV,
TMZ, and RT in newly-diagnosed GBM has reached
accrual, with initial results presented in abstract form
[25]. The Avaglio study demonstrated improved PFS,
however, the interim analysis of OS did not reach statis-
tical significance [25]. The RTOG has completed accrual
on a similar study, 0825, and results are pending.
In our current study, the most frequent failure location
following radiation, BEV, and TMZ for GBM was distant
(subependymal and deep white matter) with 7/12 pa-
tients (58%) while in-field failure was less common (3/12
patients, 25%). Without examining the brain tissue of a
patient who experienced a tumor recurrence following
treatment with radiation, BEV, and TMZ, it is difficult to
determine the precise role that these biological agents
play. BEV may have only blunted the ability of T1 +
GAD to detect the recurrence of GBM and not actually
eradicated the tumor in the in-field area. Future
advances in the treatment of GBM with radiation, BEV,
and TMZ will shed light on whether BEV affects the bio-
logical tumor composition to improve survival for pa-
tients with GBM. Pattern of failure analysis for patients
on the Avaglio and RTOG 0825 studies may also further
the understanding of this regimen.
Conclusion
Combined modality therapy of radiation, BEV, and TMZ
to treat GBM was well tolerated in the present study.
Similar to other reports, BEV blunted the ability of T1 +
GAD to detect recurrence of GBM. The predominant
out-of-field patterns of failure in our cohort of radiation
with the biological agents BEV and TMZ have not been
previously reported. Additional follow-up is warranted
to determine whether BEV alters the underlying tumor
biology to improve survival or whether the imaging is
modified. These data indicate that the currently used
target expansions for radiation may not be appropriate
in combination with TMZ and BEV.
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